E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).

被引：0

作者：

Hochster, Howard S.

Catalano, Paul J.

Mitchell, Edith P.

Cohen, Deirdre Jill

O'Dwyer, Peter J.

Benson, Al Bowen

机构：

[1] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[4] NYU, Inst Canc, New York, NY USA

[5] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[6] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS3665

引用

页数：1